

1 **Determinants of anti-retroviral therapy adherence among adolescents living**  
2 **with HIV in the Kingdom of Eswatini**

3

4 Londiwe D. Hlophe<sup>1\*</sup>, Constance S. Shumba<sup>2</sup>, Diribsa T. Bedada<sup>1,3</sup>, Peter S.  
5 Nyasulu<sup>1,4\*</sup>

6

7 Affiliations

8 <sup>1</sup> Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences,  
9 Stellenbosch University, Cape Town, South Africa

10 <sup>2</sup> School of Nursing and Midwifery, Aga Khan University, Nairobi, Kenya

11 <sup>3</sup> Department of Public Health, College of Health Sciences, National Defence  
12 University, Addis Ababa, Ethiopia

13 <sup>4</sup> Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health  
14 Sciences, University of the Witwatersrand, Johannesburg, South Africa

15

16 \*Corresponding authors

17 Email: [londiwehlope85@gmail.com](mailto:londiwehlope85@gmail.com) (LDH)

18 [pnyasulu@sun.ac.za](mailto:pnyasulu@sun.ac.za) (PSN)

19

20

## 21 Abstract

22 **Background:** The success of antiretroviral therapy (ART) depends on a high level of  
23 adherence to the life-long therapy of 95% and above. However, in Eswatini,  
24 adolescents and young people aged 15 to 24 years, have poor ART adherence as  
25 evidenced by low viral load (VL) suppression rates (76% and 63% among female and  
26 males respectively) compared to the general population (96%). The wide age-band of  
27 15 to 24 years in reporting viral suppression rates means that adolescent specific data  
28 is limited, and younger adolescents aged 10-14 years are excluded. This study  
29 explored the level of ART adherence and associated factors among adolescents living  
30 with HIV (ALHIV) aged 10 to 19 years on ART in Eswatini.

31 **Methods:** We performed a retrospective analysis of 911 medical records of ALHIV  
32 aged 10 to 19 years on ART for at least a month in Eswatini for the period 1<sup>st</sup> January  
33 2017 to 30<sup>th</sup> September 2022. Bivariate logistic regression was fitted for each predictor  
34 variable. Missing values were imputed using multiple imputation by chained equation  
35 (MICE). Statistically significant ( $p$ -value  $\leq 0.2$ ) predictor variables were included in a  
36 multivariable logistic regression model.  $P$ -value  $\leq 0.05$  was used to declare statistical  
37 significance in the final regression model.

38 **Results:** ART adherence of 88.5% was recorded with higher adherence among males  
39 (88.9%) than females (87.8%). Hhohho region had highest adherence (90.7%) while  
40 Shiselweni region had lowest adherence (82%). Adherence was low among ALHIV  
41 with a non-suppressed baseline VL result (65.3%) and those assigned to multi-month  
42 ART model of care at ART initiation (66.7%). The Shiselweni region (OR 0.47; 95%CI  
43 0.26-2.78), suppressed baseline VL result (OR 5.49; 95%CI 3.36-8.96) and assigned  
44 to the main-stream ART care model (OR 0.22; 95%CI 0.05-0.95) were statistically

45 associated with ART adherence. In the multivariable regression analysis, only  
46 Shiselweni region and suppressed baseline VL result were statistically associated with  
47 ART adherence.

48 **Conclusion:** Eswatini ALHIV have a low ART adherence compared to general  
49 population. Shiselweni region is negatively associated with ART adherence among  
50 ALHIV while a suppressed baseline VL is positively associated with improved ART  
51 adherence. There is therefore a need to intensify interventions aimed at early ART  
52 initiation and intensive follow-up and support among ALHIV especially in the  
53 Shiselweni region.

54 **Keywords:** ART adherence; viral load suppression; adolescents living with HIV;  
55 Kingdom of Eswatini

56

57

58

59

60

61

62

63

64

65

## 66 1. Background

67 Globally, commendable strides have been made in attaining an optimum antiretroviral  
68 therapy (ART) adherence rate, and accordingly achieving viral load suppression (VLS)  
69 among people living with HIV (PLHIV). For instance, in the year 2021, 75% of PLHIV  
70 were on ART and 68% of these were virally suppressed [1,2]. In eastern and southern  
71 Africa which is home to 54% of all PLHIV globally, 79% of PLHIV were on ART, and  
72 of these, 78% were virally suppressed in 2021 [3,4].

73 ART adherence is defined as *“the extent to which a personal behaviour in taking HIV*  
74 *medication, attending scheduled clinic appointments, following a diet or certain*  
75 *behaviour corresponds to the treatment and care plan conjointly agreed between the*  
76 *person living with HIV and the health worker”* [5]. Optimum ART adherence, defined  
77 as 95% and above of correctly taking medication is a primary determinant of VLS [6].  
78 Viral load suppression is viral load <1000 RNA copies per ml of blood and is critical in  
79 prevention of transmission of HIV to sero-negative partner, disease progression,  
80 opportunistic diseases, and AIDS-related deaths [5–7].

81 However, consistent with the evidence, globally, high ART uptake and VLS rates are  
82 only observed among the general population with adolescents reporting lower rates,  
83 yet adolescents account for 5% of all PLHIV [3,8]. The rates are even lower among  
84 ALHIV in sub-Saharan Africa (SSA) [1,3,9–11]. For instance, in 2021, VLS was only  
85 30% among the 43% ALHIV on ART in SSA [12]. Furthermore, a systematic review  
86 including studies conducted between 2010 and 2022, reported an ART adherence rate  
87 of 65% and a VLS rate of 55% among ALHIV in SSA [13]. Similarly, studies conducted  
88 in South Africa, Kenya, Tanzania, and Uganda have reported even lower ART  
89 adherence rate ranging from 59% to 65% and VLS ranging from 22% to 73% [14–19].

90 Several factors associated with ART adherence have been identified among studies.  
91 These include age, sex, missing clinical appointment, presence of opportunistic  
92 diseases, duration on ART, ART regimen, family support, type of health facility, World  
93 Health Organization (WHO) clinical staging, VLS, and CD4-count [10,18,20–23].

94 The Kingdom of Eswatini formerly known as Swaziland has the highest Human  
95 Immuno-deficiency Virus (HIV) prevalence of 27% globally with an incidence of 1.4  
96 among those 15 years and above [24]. Females are mostly affected in the country with  
97 an HIV prevalence of 32.5% compared to 20.4% among males [25]. Secondly, the HIV  
98 prevalence is disproportionately high at 7.3% among female adolescents aged 15 to 19  
99 years compared to their male counterparts at 3.9% [25]. HIV prevention and  
100 management is critical among adolescents not only in Eswatini, but in the sub-Saharan  
101 Africa (SSA) region which is home to 90% of adolescents living with HIV (ALHIV) [3].

102 Eswatini is among the first countries globally to meet the 95-95-95 (95% people living  
103 with HIV knowing their HIV status, 95% of these on ART and 95% of those on ART  
104 viral load suppressed) UNAIDS global targets in the general population ahead of the  
105 year 2030 [26]. Viral load suppression (VLS) was reported to be 96% as of 2022 in the  
106 country, from 91% in 2017 [25,26]. This has been attributed to the uninterrupted  
107 access and availability of antiretroviral therapy (ART) among those testing positive to  
108 HIV and programmes aimed at supporting ART adherence [27].

109 However, these positive gains are only observed among the general population while  
110 ALHIV still present poor HIV treatment outcomes [28]. For instance, in 2017 Eswatini  
111 reported 89% of the people living with HIV (PLHIV) on ART with 91% of them virally  
112 suppressed. However, among ALHIV and young people, only 81.7% were on ART and  
113 76.4% virally suppressed [25]. The discrepancies in viral load suppression rate among

114 adolescents and general population, are an indication of poor HIV prevention and  
115 management, particularly poor ART adherence among ALHIV.

116 Unfortunately, there is limited HIV data on adolescents aged 10 to 19 years in Eswatini  
117 due to the wide description age-band of 15 to 24 years. Therefore, this study aimed to  
118 assess the level of ART adherence and associated factors among ALHIV aged 10 to  
119 19 years on ART in Eswatini.

120

## 121 **2. Methods**

### 122 **2.1 Study design and population**

123 This was a retrospective study design which used data from the Eswatini Ministry of  
124 Health, Health Management Information System [HMIS]. Data extraction was done  
125 using a chart abstraction tool from the Client Management Information System (CMIS)  
126 for adolescents who accessed care and tested HIV positive between the periods of  
127 January 2017 and 30 September 2022. In 2017, Eswatini adopted and implemented  
128 the universal test and treat guidelines and the same year, the CMIS was rolled out in  
129 all the health facilities in the country [29]. The CMIS is a national electronic medical  
130 record system aimed at tracking and caring for patients visiting health facilities in the  
131 country. The system consolidates all the medical history of patients into one data set  
132 allowing for comprehensive health information of patients [29].

133

### 134 **2.2 Inclusion and exclusion criteria**

135 This study included ALHIV who were enrolled and initiated in ART at age 10–19 with  
136 either vertical or horizontal HIV infection from 1<sup>st</sup> January 2017 to 30<sup>th</sup> September  
137 2022. Only ALHIV and had been on ART for at least a month were included in this  
138 study. ALHIV who transitioned from paediatric care were excluded from this study.  
139 Secondly, ALHIV whose records had missing details of latest or current viral load (VL)  
140 result in the CMIS database were excluded from the study. Current or latest VL result  
141 was defined as the last available VL result.

142

### 143 **2.3 Ethical approval**

144 Approval to carry out the study was sought from the Eswatini Health and Human  
145 Research Review Board of the Ministry of Health and a waiver of consent was obtained  
146 from the Board (Protocol Reference Number: EHHRRB103/2022). A waiver not to  
147 acquire participants' informed consent was granted by the same board as this study  
148 involved secondary data analysis. Anonymity was maintained by de-identifying the  
149 data and assigning codes instead of names during the chart abstraction process.

150

### 151 **2.4 Study setting**

152 The data involved ALHIV enrolled in ART care from 1<sup>st</sup> January 2017 to 30<sup>th</sup>  
153 September 2022 in the Kingdom of Eswatini and registered in CMIS database. In  
154 2015, adolescents accounted for 10% of all those in HIV treatment in the country [30].  
155 Adolescents access care through a differential ART service delivery model which  
156 includes expert client offered by lay health workers (LHWs) through Teen Clubs, multi-

157 months (3 and 6 months) refills, as well as the mainstream model [31,32]. The expert  
158 client approach involves training LHWs on HIV treatment adherence, stigma and  
159 disclosure, and HIV linkage to care and communication and counselling skills [33,34].  
160 The mainstream model also known as the standard of care model provides direct  
161 patient monitoring by a nurse or a doctor mostly for patients newly initiated to ART,  
162 with detectable VL, with ART adherence issues, or suspected treatment failure [35].  
163 In 2021, there were 10,153 ALHIV in the country while there were 81 Teen Clubs with  
164 3,742 adolescents aged 10 to 19 years as members. The country has 327 health  
165 facilities; one (1) national referral hospital, three (3) specialized hospitals, five (5)  
166 regional referral hospitals, five (5) health centres, six (6) public health units, 297 clinics  
167 of which 65 are specialized clinics, and nine (9) private hospitals [36]. These health  
168 facilities are distributed in the four regions (Hhohho, Manzini, Lubombo and  
169 Shiselweni) of the country with the national referral hospital in the Hhohho region.

170

## 171 **2.5 Study sample**

172 A total 3,420 ALHIV aged 10 to 19 were enrolled on ART care between 1<sup>st</sup> January  
173 2017 and 30<sup>th</sup> September 2022. Of these, 911 were included in the analysis as they  
174 met the inclusion criteria. Among the 911, some had missing data in one or more  
175 variables. We imputed the missing information using Multivariate Imputation by  
176 Chained Equations (MICE) for the variables we decided to include into the final  
177 multivariable regression model.

178

## 179 **2.6 Measurements**



180 All participants were followed for the period between January 2017 up until September  
181 2022. Only ALHIV enrolled on ART between 1<sup>st</sup> January 2017 and September 2022  
182 were included in this study. Our primary outcome was ART adherence defined as 95%  
183 of correctly taking ART which was estimated using the viral load suppression rate  
184 where viral load suppression was defined as viral load <1000 RNA copies per ml of  
185 blood, a standard VLS measurement used in Eswatini [37].

186 Predictor variables included: demographic and social factors (sex, age, region), HIV  
187 factors (age at diagnosis, baseline VL result, latest viral load result, ART start date,  
188 time on ART, model of ART care at initiation, latest or current model of ART care,  
189 regimen, CD4 count result, and WHO clinical staging), and facility factors (facility  
190 ownership). Baseline VL result was defined as the first VL result after a positive HIV  
191 diagnosis. Facility ownership included government, non-government, private and  
192 mission.

193

## 194 **2.7 Statistical analysis**

195 The dataset in Excel was exported to Stata for the data analysis, and the analysis was  
196 done using the Stata statistical software, release 16, College Station, TX, Stata Corp  
197 LLC.

198 Data analyses were conducted at descriptive, bivariate, and multivariable levels.  
199 Continuous variables (age, years at HIV diagnosis and years on ART) were presented  
200 as means with standard deviations and categorical variables were presented as  
201 frequencies and percentages. Differences in characteristics between ALHIV who were  
202 adherent versus those who were non-adherent were assessed using the chi-square

203 test. Associations between ART adherent and independent variables were examined  
204 using the Pearson' chi-square test.

205 Variables that were significantly associated with ART adherence at bivariate analysis  
206 at significance level of  $\leq 0.2$  were selected and included in the multivariable regression  
207 model. Age and sex were included despite their lack statistical significance. Due to  
208 high missing data in some of the variables, a Multiple Imputation by Chained Equation  
209 (MICE) was conducted to impute the missing values.

210 Backward elimination was used in building the final model whereby variables which  
211 did not contribute at p-value  $<0.05$  were eliminated and a new model fitted. All  
212 variables that were significant at  $p<0.05$  were kept in the final multivariable logistic  
213 regression model.

214

## 215 **3. Results**

### 216 **3.1 Socio-demographic characteristics of participants**

217 A total of 3420 medical records were reviewed of which only 911 were included in the  
218 analysis. Six-hundred-and-six (66.6%) adolescents were in the age group 15 to 19  
219 years and 155 (60%) were females. The mean age of the ALHIV and on ART was 16.3  
220 (SD 3.3). Majority (355; 39%) of the adolescents were from the Hhohho region while  
221 only 133 (15%) were from the Shiselweni region (Table 1).

222

### 223 **3.2 Clinical and Treatment-Related Characteristics**

224 The average age at diagnosis of adolescents was 14 years (SD 4.2). Most adolescents  
 225 (355; 70%) were enrolled under government owned health facilities while only 123  
 226 (13.5%) were enrolled in both private and non-government health facilities.  
 227 Government health facilities include both military and non-military health facilities.  
 228 Among adolescents with a recorded CD4 count results, 158 (60%) were on either  
 229 World Health Organization (WHO) clinical stage three or stage 4 as a baseline CD4  
 230 count result. As of 2022 (latest CD4 result), only 81 out of 141 adolescents with CD4  
 231 count result were on either of these stages. Seven-hundred-and-fifty-eight (83%) of  
 232 the adolescents had been on ART for 2 years and above. At baseline, 714 (88%)  
 233 adolescents were virally load suppressed (Table 1). Overall, ART adherence was  
 234 88.5% among adolescents. The age group 15 to 19 years had higher adherence  
 235 (89.3%) compared to 10-14 years (86.9%). Hhohho region recorded 90.7% ART  
 236 adherence followed by Manzini (89.5%), Lubombo (87.50%), while Shiselweni had the  
 237 lowest adherence rate of 81.95% (Table 1).

238

239 **Table 1: Characteristics of study participants stratified by ART adherence**

Variable	Total N=911 <sup>a</sup>	Adherence (n, %)	Non-adherent (n, %)	p-value
<b>Age group</b>				
10-14	305	265 (86.89%)	40 (13.11%)	0.287
15-19	606	541 (89.27%)	65 (10.73%)	
<b>Sex</b>				
Female	551	490 (88.93%)	61 (11.07%)	0.595
Male	360	316 (87.78%)	44 (12.22%)	
<b>Region</b>				
Hhohho	355	322 (90.70%)	33 (9.30%)	0.052
Lubombo	184	161 (87.50%)	23 (12.5%)	
Manzini	239	214 (89.54%)	25 (10.46%)	

Shiselweni	133	109 (81.95%)	24 (18.05%)	
<b>Facility Ownership</b>				
Government	641	567 (88.46%)	74 (11.54%)	0.945
NGO	123	108 (87.8%)	15 (12.2%)	
Faith-based	147	131 (89.12%)	16 (10.88%)	
<b>ART Duration</b>				
<2 years	153	139 (90.85%)	14 (9.15%)	0.313
≥2years	758	667 (87.99%)	91 (12.01%)	
<b>ART Regimen</b>				
1 <sup>st</sup> Line	430	387 (90%)	43 (10%)	0.074
2 <sup>nd</sup> Line	17	13 (76.5%)	4 (23.5%)	
<b>Baseline WHO Stage</b>				
I-II	104	91 (87.5%)	13 (12.5%)	0.549
III-IV	158	142 (89.87%)	16 (10.13%)	
<b>Latest WHO Stage</b>				
I-II	60	48 (80%)	12 (20.0%)	0.143
III-IV	81	72 (88.89%)	9 (11.11%)	
<b>Baseline VLS</b>				
No	98	64 (65.31%)	34 (34.69%)	0.0000*
Yes	714	651 (91.18%)	63 (8.82%)	
<b>ART Model of Care at Initiation</b>				
Multi-Months	3	2 (66.67%)	1 (33.33%)	0.393
Mainstream	416	371 (89.18%)	45 (10.87%)	
Teen Clubs	37	34 (91.89%)	3 (8.11%)	
<b>Current Model of ART Care</b>				
Multi-Months	66	64 (96.97%)	2 (3.03%)	0.058
Mainstream	433	379 (87.53%)	54 (12.47%)	
Teen Clubs	338	302 (89.35%)	36 (10.65%)	
Fast Track	17	17 (100%)	0	

240 \*Statistically significant

241 <sup>a</sup> some sample sizes for variables may not add up to N due to missing data

242

### 243 3.3 Factors Associated with ART Adherence among

#### 244 ALHIV

245 In the bivariate logistic regression analysis, Shiselweni region, viral load suppressed  
246 at initiation and mainstream at current ART care model were statistically significant  
247 predictors and were fitted in the multivariable logistic regression model (Table 2). In  
248 the multivariable regression model (Table 3), only Shiselweni and baseline or initial  
249 viral load suppressed were predictors of ART adherence.

250 The odds of adolescents from Shiselweni region were negatively associated  
251 (OR=0.54, 95%CI: 0.17-0.96) with ART adherence than adolescents from the other  
252 region of the country. The odds of adolescents with a suppressed baseline viral load  
253 were (OR=6.22, 95% CI: 4.13-10.56) almost six-fold likely to adhere to ART compared  
254 to those who were non-virally load suppressed (Table 3).

255

256 **Table 2: Factors associated with ART adherence among ALHIV**

Variable	OR	p-value	95% CI
<b>Age</b>			
10-14	Ref		
15-19	1.26	0.287	0.83-1.91
<b>Sex</b>			
Female	Ref		
Male	0.89	0.595	0.59-1.35
<b>Region</b>			
Hhohho	Ref		
Lubombo	0.72	0.249	0.41-1.26
Manzini	0.88	0.639	0.51-1.52
Shiselweni	0.47	0.008*	0.26-2.78
<b>Facility Ownership</b>			

Government	Ref		
Non-government and Private	0.92	0.789	0.51-1.67
Faith-based	1.07	0.820	0.60-1.89
<b>ART Duration</b>			
<2 years	Ref		
≥2 years	0.74	0.315	0.41-1.33
<b>Regimen</b>			
1 <sup>st</sup> Line	Ref		
2 <sup>nd</sup> Line	0.36	0.086	0.11-1.16
<b>Baseline VLS</b>			
No	Ref		
Yes	5.49	0.000*	3.36-8.96
<b>Baseline WHO stage</b>			
I-II	Ref		
III-IV	1.27	0.550	0.58-2.78
<b>Latest WHO stage</b>			
I-II	Ref		
III-IV	2	0.148	0.78-5.11
<b>ART Model of Care at Initiation</b>			
Multi-Month	Ref		
Mainstream	4.12	0.251	0.37-46.37
Teen Club	5.67	0.204	0.39-82.24
<b>Current ART Model of Care</b>			
Multi-Month	Ref		
Mainstream	0.22	0.038*	0.05-0.92
Teen Club	0.26	0.070	0.06-1.12

258

259 **Table 3: Multivariate Logistic Regression showing factors associated with ART**

260 **adherence among ALHIV**

Variable	OR	p-value	95% CI
<b>Age group</b>			
10-14	Ref		
15-19	1.49	0.231	0.81-2.54
<b>Sex</b>			
Female	Ref		
Male	1.35	0.632	0.72-1.98
<b>Region</b>			
Hhohho	Ref		
Lubombo	0.86	0.412	0.52-1.73
Manzini	0.90	0.512	0.63-1.79
Shiselweni	0.54	0.029*	0.17-0.96
<b>Baseline VLS</b>			
No	Ref		
Yes	6.22	0.001*	4.13-10.56
<b>Current ART Model of Care</b>			
Multi-Month	Ref		
Mainstream	1.23	0.661	0.67-2.23
Teen Clubs	0.94	0.623	0.58-2.14
Constant	8.22	0.031	2.65-24.812

261 \*Statistically significant

262

263

## 264 4. Discussion

265 The study revealed the determinants of ART adherence among ALHIV in the Kingdom  
266 of Eswatini. In this study, the mean age was 16.3 (SD 3.3) years with more females  
267 (551, 60%) compared to males (360, 40%). On average, adolescents were initiated on  
268 ART at the age of 14 years (SD 4.2). The study discovered that overall, ART  
269 adherence among ALHIV was sub-optimal at 88.5% which is lower than the 95% ART  
270 adherence rate required for suppressed viral load. When compared to other studies,  
271 ART adherence among Swati adolescents was higher than in studies conducted  
272 among ALHIV in South Africa (65%), Kenya (76%) and Zimbabwe (28%) while  
273 comparable with studies conducted in Nigeria (85%), Uganda (80%), Cameroon (83%)  
274 [10,16,22,38–40]. These discrepancies among the countries could be due to the  
275 differences in outcome measurements, settings, sample sizes, and study designs as  
276 explained in a study conducted in Ethiopia among children on ART [21].

277 Nevertheless, an ART adherence rate below 95% is associated with unsuppressed  
278 viral load which is further associated with opportunistic infections, drug resistance and  
279 subsequently death [7]. For instance, in two studies conducted in South Africa, lower  
280 ART adherence rate was statistically associated with increased opportunistic  
281 infections and a two-fold (OR 1.98) likelihood of a detectable viral load [41,42]. Another  
282 study conducted among ALHIV in South Africa reported that poor ART adherence was  
283 also associated with virologic failure [43]. A study conducted in Liberia also revealed  
284 that poor ART adherence was associated with loss to follow up and experiences of  
285 drug side effects [44].

286 Secondly, the study findings indicate that Shiselweni region is a predictor of poor ART  
287 adherence compared to the other regions. This finding is not comparable to the



288 national findings which indicate that generally the Shiselweni region has the highest  
289 HIV prevalence (26.5%) compared to the other regions but not statistically associated  
290 with either viral load suppression or ART adherence [27]. The Swaziland HIV  
291 Incidence measurement survey (SHIMS II) also reported that the different HIV  
292 prevalence rates in the four regions of the country had no significant difference [25].  
293 However, findings of this study have revealed that there is an association between  
294 ART adherence and region among ALHIV. This could be because previous studies  
295 were conducted among the general population or adult population while this study was  
296 conducted among adolescent age group. Studies conducted in the Shiselweni region  
297 revealed that the universal test and treat (UTT) HIV program has been associated with  
298 low retention to care partly due to status non-acceptance by those tested positive and  
299 other factors such as transport costs and distance to health facilities [45–47]. The  
300 Shiselweni region is ranked the poorest region in the country with high food and water  
301 insecurities [46,48] . According to the Eswatini operational plan of 2020, the population  
302 of the Shiselweni region is hard-to-reach with limited access to health services and  
303 HIV prevention, control, and management services such as HIV testing and VL testing  
304 since it is dynamic and very evanescent because of the recent influx and growth of  
305 textile factories, and it harbours the main truck route and border gate [48]. The region  
306 is therefore a hot spot for at-risk population [48]. The delayed initiation of ART due to  
307 low testing in the Shiselweni region has been associated with poor ART outcomes  
308 such as low viral load suppression among those who are eventually tested in the  
309 region [46,47].

310 According to studies conducted in Uganda and South Africa, retention to care was a  
311 positive predictor of ART adherence while a study conducted in South Africa also  
312 revealed that distance to health facilitator was statistically associated with ART

313 adherence [18,49]. Studies aimed at improving the financial capacity of ALHIV have  
314 reported a positive association with retention to care and ART adherence [50–54]. This  
315 has been facilitated by financial incentives aimed at assisting ALHIV with money for  
316 honouring their hospital appointments, curbing food insecurities among others. For  
317 instance, a study conducted in Uganda which was aimed at evaluating the efficacy of  
318 economic incentive in improving ART outcomes such as viral load suppression and  
319 adherence among ALHIV, presented a ten-fold increase among those receiving the  
320 economic incentive compared to standard of care [52]. However, status acceptability  
321 has been reported to be associated with retention to care and ART adherence. In  
322 studies conducted in Zambia, Tanzania and South Africa, early status disclosure  
323 among adolescents was associated with early acceptability of status and thus  
324 treatment adherence [55–57] . Additionally, a study conducted by Cluver *et al.* (2015)  
325 revealed that adolescents who had their status disclosed early were three times likely  
326 to be retained in care and thus improved ART adherence [55] . However, other studies  
327 have reported that adolescents whose status were revealed early were most likely to  
328 miss medication doses due to treatment fatigue [49,58]. These contradicting findings  
329 are justified by Ankrah *et al.* (2016) because of lack of support system among ALHIV  
330 especially older adolescents as care-giver responsibility reduces and adolescents are  
331 at a self-discovery stage [59]. Nevertheless, early treatment to initiation and adherence  
332 to the treatment are critical in improving ART outcomes. WHO guidelines have  
333 established a positive association between early treatment initiation and improved  
334 ART outcomes such as viral load suppression which are associated with optimum ART  
335 adherence among those on ART [6]. Early initiation to ART is facilitated by the  
336 availability of health services promoting HIV testing for early diagnosis and subsequent  
337 treatment through the UTT approach [6,18].

338 Lastly, the study revealed that baseline viral load suppression is a positive predictor  
339 for ART adherence as revealed in other studies. Numerous studies have reported the  
340 association between VLS and ART adherence. High viral load suppression is  
341 positively associated with optimum ART adherence while non-viral load suppression  
342 is a predictor for poor ART adherence [60–67]. For instance, in a study conducted in  
343 Kenya, adolescents and children with a suppressed viral load were mostly likely to  
344 adhere to treatment compared to those with a high viral load at ART initiation [68].  
345 Furthermore, the UTT has been based on scientifically proven evidence that early  
346 initiation to ART is effective in ensuring positive ART outcome such as reduced AIDS  
347 related morbidity and mortality [69–73]. The positive ART outcomes are enabled by  
348 the low viral load which associated with ART adherence.

349 The strength of our study is that the results demonstrate the current ART adherence  
350 level and key associated factors (demographic and social factors, HIV factors, and  
351 facility factors) among ALHIV aged 10 to 19 years, a population group normally  
352 reported with young adults and paediatrics. Secondly, since the study used the  
353 national dataset, the study results can extrapolate the current ART adherence situation  
354 in Eswatini specifically among ALHIV. Additionally, since secondary data was used,  
355 recall and reporting bias were eliminated. Also, the data collection process was  
356 informed by professionalism and expertise, and not associated with research thus was  
357 not subject to interview bias. Lastly, being the only study conducted among  
358 adolescents within this age group, our study can contribute to informing policies, plans,  
359 and service delivery strategies for preventing and controlling poor ART adherence  
360 among ALHIV in Eswatini.

361 Nonetheless, some limitations should be considered when interpreting the findings of  
362 this study. Firstly, this was a retrospective study that used secondary data for analysis

363 that was not intentionally collected for this study, and therefore limited the study in  
364 evaluating other predictors of ART adherence which were not covered in the records.  
365 Secondly, being a secondary dataset made the data prone to missing variables due  
366 to incomplete documentation. However, we are confident that the available data  
367 provide true estimation as it was captured by qualified health professionals.

368

## 369 **5. Conclusions**

370 In conclusion, our results demonstrate that ART adherence is sub-optimum among  
371 ALHIV in Eswatini despite the positive progress in attaining the 95-95-95 UNAIDS  
372 2030 target by the general population. It is critical to better understand why  
373 adolescents have a sub-optimum adherence rate and device strategies aimed at  
374 improving ART adherence among ALHIV in Eswatini. These results highlight an urgent  
375 need to innovate strategies aimed at improving early ART initiation and intensive  
376 follow-up and support among ALHIV especially in the Shiselweni region.

377

## 378 **6. List of abbreviations**

379 AIDS, Acquired Immune Deficiency Syndrome; OR, Odds ratio; ART, Anti-Retroviral  
380 Therapy; HIV, Human Immunodeficiency Virus; VL, Viral Load; VLS, Viral Load  
381 suppression; ALHIV, Adolescents Living with HIV; PLHIV, People Living with HIV;  
382 WHO, World Health Organization; CMIS, Client Management Information System;  
383 SSA, sub-Saharan Africa; LHW, Lay Health Worker; UTT, Universal Test and Treat

384

## 385 **7. Declaration**

386 **Ethics approval and consent to participate:** Ethical approval for conducting the  
387 study was sought from the Eswatini Health and Human Research Review Board of the  
388 Ministry of Health and a waiver of consent was obtained from the Board since the  
389 study used secondary data (Protocol Reference Number: EHHRRB103/2022).

390 **Consent of publication:** The Eswatini Health and Human Research Review Board of  
391 the Ministry of Health granted the consent for publication of the findings of the study.

392 **Availability of data and materials:** Data underlying the findings of the study are  
393 included in the paper.

394 **Competing interests:** The authors report that there was no conflict of interest in this  
395 work.

396 **Funding:** The authors received no specific funding for this work.

### 397 **Authors' contribution:**

398 Conceptualization: Londiwe D. Hlophe, Peter S. Nyasulu, Constance S. Shumba

399 Dara curation: Londiwe D. Hlophe, Diribsa T. Bedada

400 Formal analysis: Londiwe D. Hlophe, Diribsa T. Bedada

401 Investigation: Londiwe D. Hlophe

402 Methodology: Londiwe D. Hlophe, Diribsa T. Bedada, Constance S. Shumba, Peter S.

403 Nyasulu

404 Writing-original draft preparation: Londiwe D. Hlophe

405 Writing- review and editing: Londiwe D. Hlophe, Diribsa T. Bedada, Constance S.  
406 Shumba, Peter S. Nyasulu

407 **Acknowledgement:** The authors would like to thank the management and staff from  
408 the Ministry of Health; Health Management Information System for the support  
409 provided during the duration of the study. Special gratitude is also forwarded to Dr.  
410 Garikai Chemhaka for his valuable support throughout the study.

411

412

## 413 **References**

- 414 1. UNAIDS. Global HIV & AIDS statistics — Fact sheet | UNAIDS [Internet]. 2022  
415 [cited 2021 Aug 24]. Available from: [https://www.unaids.org/en/resources/fact-](https://www.unaids.org/en/resources/fact-sheet)  
416 [sheet](https://www.unaids.org/en/resources/fact-sheet)
- 417 2. UNICEF. HIV Statistics - Global and Regional Trends - UNICEF DATA  
418 [Internet]. 2021 [cited 2021 Aug 24]. Available from:  
419 <https://data.unicef.org/topic/hivaids/global-regional-trends/>
- 420 3. UNICEF. HIV and AIDS in Adolescents - UNICEF Data [Internet]. 2021 [cited  
421 2021 Jan 12]. Available from: <https://data.unicef.org/topic/adolescents/hiv-aids/>
- 422 4. UNAIDS. UNAIDS 2021 epidemiological estimates. 2021 [cited 2021 Aug 24].  
423 Global HIV & AIDS statistics — Fact sheet | UNAIDS. Available from:  
424 <https://www.unaids.org/en/resources/fact-sheet>

- 425 5. WHO. Global HIV Programme [Internet]. 2022 [cited 2022 Oct 7]. Available  
426 from: [https://www.who.int/teams/global-hiv-hepatitis-and-stis-](https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/treatment/service-delivery-adherence-retention)  
427 [programmes/hiv/treatment/service-delivery-adherence-retention](https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/treatment/service-delivery-adherence-retention)
- 428 6. WHO. WHO publishes new Consolidated HIV guidelines for prevention,  
429 treatment, service delivery & monitoring [Internet]. 2021 [cited 2022 Aug 10].  
430 Available from: [https://www.who.int/news/item/16-07-2021-who-publishes-new-](https://www.who.int/news/item/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring)  
431 [consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-](https://www.who.int/news/item/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring)  
432 [monitoring](https://www.who.int/news/item/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring)
- 433 7. Hine P, Smith R, Eshun-Wilson I, Orrell C, Cohen K, Leeflang MMG, et al.  
434 Measures of antiretroviral adherence for detecting viral non-suppression in  
435 people living with HIV. Cochrane Database of Systematic Reviews.  
436 2018;2018(7).
- 437 8. UNAIDS. Global HIV & AIDS statistics — Fact sheet | UNAIDS [Internet]. 2021  
438 [cited 2021 Oct 15]. Available from: [https://www.unaids.org/en/resources/fact-](https://www.unaids.org/en/resources/fact-sheet)  
439 [sheet](https://www.unaids.org/en/resources/fact-sheet)
- 440 9. Adejumo OA, Malee KM, Ryscavage P, Hunter SJ, Taiwo BO. Contemporary  
441 issues on the epidemiology and antiretroviral adherence of HIV-infected  
442 adolescents in sub-Saharan Africa: A narrative review. J Int AIDS Soc  
443 [Internet]. 2015;18(1):20049. Available from:  
444 <http://dx.doi.org/10.7448/IAS.18.1.20049>
- 445 10. N Tanyi W, Gachuno O, Odero T, Farquhar C, Kimosop D, Mayi A. Factors  
446 affecting adherence to antiretroviral therapy among children and adolescents

- 447 living with HIV in the Mbita Sub County Hospital, Homa Bay- Kenya. Afr Health  
448 Sci. 2021 May 23;21(1):18–24.
- 449 11. Amour MA, Shayo GA, Matee MM, Machumi L, Rugarabamu A, Aris EA, et al.  
450 Predictors of mortality among adolescents and young adults living with HIV on  
451 antiretroviral therapy in Dar es Salaam, Tanzania: a retrospective cohort study.  
452 J Int AIDS Soc [Internet]. 2022 Feb 1 [cited 2022 Aug 3];25(2):25886.  
453 Available from: [/pmc/articles/PMC8863353/](https://pubmed.ncbi.nlm.nih.gov/38863353/)
- 454 12. Vreeman RC, Rakhmanina NY, Nyandiko WM, Puthanakit T, Kantor R. Are we  
455 there yet? 40 years of successes and challenges for children and adolescents  
456 living with HIV. J Int AIDS Soc [Internet]. 2021 Jun 1 [cited 2022 Jul 18];24(6):  
457 e25759. Available from:  
458 <https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25759>
- 459 13. Hlophe LD, Jacques L. Tamuzi, Constance S. Shumba PSN. Barriers and  
460 facilitators to anti-retroviral therapy adherence among adolescents aged 10 to  
461 19 years living with HIV in sub-Saharan Africa: A mixed-methods systematic  
462 review and meta-analysis. PLoS One [Internet]. 2023 Mar 18;18(5): e0276411.  
463 Available from: <http://dx.doi.org/10.1371/journal.pone.0276411>
- 464 14. Bitwale NZ, Mnzava DP, Kimaro FD, Jacob T, Mpondo BCTT, Jumanne S.  
465 Prevalence and Factors Associated with Virological Treatment Failure among  
466 Children and Adolescents on Antiretroviral Therapy Attending HIV/AIDS Care  
467 and Treatment Clinics in Dodoma Municipality, Central Tanzania. J Pediatric  
468 Infect Dis Soc. 2021 Mar;10(2):131–40.



- 469 15. Brathwaite R, Ssewamala FM, Neilands TB, Okumu M, Mutumba M, Damulira  
470 C, et al. Predicting the individualized risk of poor adherence to ART medication  
471 among adolescents living with HIV in Uganda: the Suubi+Adherence study. *J*  
472 *Int AIDS Soc.* 2021 Jun;24(6): e25756.
- 473 16. Haghghat R, Toska E, Bungane N, Cluver L. The HIV care cascade for  
474 adolescents initiated on antiretroviral therapy in a health district of South  
475 Africa: a retrospective cohort study. *BMC Infect Dis* [Internet]. 2021 Jan [cited  
476 2021 Aug 20];21(1):60. Available from: [https://doi.org/10.1186/s12879-020-](https://doi.org/10.1186/s12879-020-05742-9)  
477 [05742-9](https://doi.org/10.1186/s12879-020-05742-9)
- 478 17. Zhou S, Cluver L, Shenderovich Y, Toska E. Uncovering ART adherence  
479 inconsistencies: An assessment of sustained adherence among adolescents in  
480 South Africa. *J Int AIDS Soc* [Internet]. 2021 Oct;24(10): e25832. Available  
481 from:  
482 [http://onlinelibrary.wiley.com/doi/10.1002/jia2.25832/full%7Chttps://doi.org/10.](http://onlinelibrary.wiley.com/doi/10.1002/jia2.25832/full%7Chttps://doi.org/10.1002/jia2.25832)  
483 [1002/jia2.25832](https://doi.org/10.1002/jia2.25832)
- 484 18. Cluver L, Pantelic M, Toska E, Orkin M, Casale M, Bungane N, et al.  
485 STACKing the odds for adolescent survival: health service factors associated  
486 with full retention in care and adherence amongst adolescents living with HIV  
487 in South Africa. *J Int AIDS Soc.* 2018 Sep;21(9): e25176.
- 488 19. Chory A, Callen G, Nyandiko W, Njoroge T, Ashimosi C, Aluoch J, et al. A Pilot  
489 Study of a Mobile Intervention to Support Mental Health and Adherence  
490 Among Adolescents Living with HIV in Western Kenya. *AIDS Behav* [Internet].  
491 2022 Jul 22 [cited 2021 Nov 24];26(1):232–42. Available from:  
492 <https://doi.org/10.1007/s10461-021-03376-9>

- 493 20. Watt MH, Maman S, Golin CE, Earp JA, Eng E, Bangdiwala SI, et al. Factors  
494 associated with self-reported adherence to antiretroviral therapy in a  
495 Tanzanian setting. *AIDS Care*. 2010 Mar;22(3):381–9.
- 496 21. GebreEyesus F, Mitku D, Tarekegn T, Temere B, Terefe T, Belete A, et al.  
497 Levels of Adherence and Associated Factors Among Children on ART Over  
498 Time in Northwest, Ethiopia: Evidence from a Multicenter Follow-Up Study.  
499 *HIV AIDS (Auckl)*. 2021; 13:829–38.
- 500 22. Bongfen MC, Torpey K, Ganle J, Ankomah A. Level of adherence and  
501 associated factors among HIV-positive adolescents on antiretroviral therapy in  
502 Cameroon. *Afr J AIDS Res*. 2020 Dec;19(4):269–75.
- 503 23. Kim MH, Mazenga AC, Yu X, Ahmed S, Paul ME, Kazembe PN, et al. High  
504 self-reported non-adherence to antiretroviral therapy amongst adolescents  
505 living with HIV in Malawi: Barriers and associated factors. *J Int AIDS Soc*.  
506 2017;20(1):1–12.
- 507 24. Justman J, Reed JB, Bicego G, Donnell D, Li K, Bock N, et al. Swaziland HIV  
508 Incidence Measurement Survey (SHIMS): a prospective national cohort study.  
509 *Lancet HIV*. 2017 Feb 1;4(2): e83–92.
- 510 25. SHIMS2. Swaziland Hiv Incidence Measurement Survey 2: a Population-  
511 Based Hiv Impact Assessment. 2017;(July 2017):1–4. Available from:  
512 [http://phia.icap.columbia.edu/wp-](http://phia.icap.columbia.edu/wp-content/uploads/2017/11/Swaziland_new.v8.pdf)  
513 [content/uploads/2017/11/Swaziland\\_new.v8.pdf](http://phia.icap.columbia.edu/wp-content/uploads/2017/11/Swaziland_new.v8.pdf)
- 514 26. PEPFAR. Eswatini surpasses UNAIDS Fast-track Targets for treatment and  
515 viral suppression - United States Department of State [Internet]. 2022 [cited

- 516 2022 Oct 14]. Available from: [https://www.state.gov/eswatini-surpasses-](https://www.state.gov/eswatini-surpasses-un-aids-fast-track-targets-for-treatment-and-viral-suppression/)  
517 [un-aids-fast-track-targets-for-treatment-and-viral-suppression/](https://www.state.gov/eswatini-surpasses-un-aids-fast-track-targets-for-treatment-and-viral-suppression/)
- 518 27. Eswatini Meets Global 95-95-95 HIV Target - Blog - The Global Fund to Fight  
519 AIDS, Tuberculosis and Malaria [Internet]. [cited 2022 Oct 14]. Available from:  
520 [https://www.theglobalfund.org/en/blog/2020-09-14-eswatini-meets-global-95-](https://www.theglobalfund.org/en/blog/2020-09-14-eswatini-meets-global-95-95-95-hiv-target/)  
521 [95-95-hiv-target/](https://www.theglobalfund.org/en/blog/2020-09-14-eswatini-meets-global-95-95-95-hiv-target/)
- 522 28. Nsibandze BS, Downing C, Poggenpoel M, Myburgh CPH. “I have been  
523 rejected so many times” experiences of female adolescents living with HIV in  
524 rural Manzini, Eswatini: A case study. *Int J Afr Nurs Sci*. 2021 Jan 1;  
525 14:100307.
- 526 29. Silvestre E. Measure Evaluation. 2017 [cited 2023 Aug 3]. p. 1 to 42  
527 Implementing Swaziland’s Client Management Information System:  
528 Stakeholder’s Views of the Process and Recommendations to Improve it.  
529 Available from: [https://www.measureevaluation.org/resources/publications/tr-](https://www.measureevaluation.org/resources/publications/tr-17-226.html)  
530 [17-226.html](https://www.measureevaluation.org/resources/publications/tr-17-226.html)
- 531 30. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al.  
532 Factors associated with virological failure and suppression after enhanced  
533 adherence counselling, in children, adolescents and adults on antiretroviral  
534 therapy for HIV in Swaziland. *PLoS One* [Internet]. 2015;10(2): e0116144.  
535 Available from: <http://dx.doi.org/10.1371/journal.pone.0116144>
- 536 31. Ness TE, Agrawal V, Guffey D, Small A, Simelane T, Dlamini S, et al. Impact  
537 of using creative arts programming to support HIV treatment in adolescents  
538 and young adults in Eswatini. *AIDS Res Ther* [Internet]. 2021 Dec 1 [cited

- 539 2022 Oct 23];18(1):1–7. Available from:  
540 [https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-021-00423-](https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-021-00423-2)  
541 2
- 542 32. Ministry of Health. Kingdom of Eswatini. Guidelines for Differentiated Service  
543 Delivery [Internet]. Mbabane; 2022 [cited 2022 Nov 13]. Available from:  
544 [https://cquin.icap.columbia.edu/wp-content/uploads/2022/07/Final\\_Policy-](https://cquin.icap.columbia.edu/wp-content/uploads/2022/07/Final_Policy-Guidelines-for-Eswatini-Differentiated-Service-Delivery.pdf)  
545 [Guidelines-for-Eswatini-Differentiated-Service-Delivery.pdf](https://cquin.icap.columbia.edu/wp-content/uploads/2022/07/Final_Policy-Guidelines-for-Eswatini-Differentiated-Service-Delivery.pdf)
- 546 33. Dlamini-Simelane T, Moyer E. Task shifting or shifting care practices? the  
547 impact of task shifting on patients' experiences and health care arrangements  
548 in Swaziland. *BMC Health Serv Res*. 2017 Jan 10;17(1).
- 549 34. Ahmed C V., Weissinger G, Teitelman A, Sabelo Dlamini N, Patience Dlamini  
550 N, Cebisile Dlamini T, et al. Expert client service delivery practices among  
551 adolescents living with HIV in Eswatini: A thematic analysis. *Child Youth Serv*  
552 *Rev*. 2022 Jan 1; 132:106309.
- 553 35. Ministry of Health. Swaziland. Swaziland Integrated HIV Management  
554 Guidelines [Internet]. 2018 [cited 2022 Nov 15]. Available from:  
555 [http://swaziaidsprogram.org/wp-content/uploads/2021/07/2018-Integrated-HIV-](http://swaziaidsprogram.org/wp-content/uploads/2021/07/2018-Integrated-HIV-Management-Guidelines_final-1.pdf)  
556 [Management-Guidelines\\_final-1.pdf](http://swaziaidsprogram.org/wp-content/uploads/2021/07/2018-Integrated-HIV-Management-Guidelines_final-1.pdf)
- 557 36. Government of the Kingdom of Eswatini. Service Availability and Readiness  
558 Assessment (SARA), 2017 [Internet]. Ministry of Health,: Mbabane. Mbabane;  
559 2017 [cited 2022 Oct 25]. Available from:  
560 [https://www.hst.org.za/publications/NonHST%20Publications/Eswatini%20SA](https://www.hst.org.za/publications/NonHST%20Publications/Eswatini%20SARA%20March%20(05%2004%202019).pdf)  
561 [RA%20March%20\(05%2004%202019\).pdf](https://www.hst.org.za/publications/NonHST%20Publications/Eswatini%20SARA%20March%20(05%2004%202019).pdf)

- 562 37. Ministry Of Health Kingdom of Swaziland. 2018-Integrated-HIV-Management-  
563 Guidelines\_final-1.pdf [Internet]. Mbabane; 2018 [cited 2022 Nov 13]. Available  
564 from: [http://swaziidsprogram.org/wp-content/uploads/2021/07/2018-](http://swaziidsprogram.org/wp-content/uploads/2021/07/2018-Integrated-HIV-Management-Guidelines_final-1.pdf)  
565 [Integrated-HIV-Management-Guidelines\\_final-1.pdf](http://swaziidsprogram.org/wp-content/uploads/2021/07/2018-Integrated-HIV-Management-Guidelines_final-1.pdf)
- 566 38. Sithole Z, Mbizvo E, Chonzi P, Mungati M, Juru TP, Shambira G, et al.  
567 Virological failure among adolescents on ART, Harare City, 2017- a case-  
568 control study. BMC Infect Dis. 2018;18(1):1–8.
- 569 39. Natukunda J, Kirabira P, Ong KIC, Shibanuma A, Jimba M. Virologic failure in  
570 HIV-positive adolescents with perfect adherence in Uganda: a cross-sectional  
571 study. Trop Med Health. 2019;47(1):1–10.
- 572 40. Meloni ST, Agaba P, Chang CA, Yiltok E, Oguiche S, Ejeliogu E, et al.  
573 Longitudinal evaluation of adherence, retention, and transition patterns of  
574 adolescents living with HIV in Nigeria. PLoS One. 2020;15(7): e0236801.
- 575 41. Cluver LD, Toska E, Orkin FM, Meinck F, Hodes R, Yakubovich AR, et al.  
576 Achieving equity in HIV-treatment outcomes: can social protection improve  
577 adolescent ART-adherence in South Africa? AIDS Care [Internet].  
578 2016;28(sup2):73–82. Available from:  
579 <http://dx.doi.org/10.1080/09540121.2016.1179008>
- 580 42. Zhou S, Cluver L, Shenderovich Y, Toska E. Uncovering ART adherence  
581 inconsistencies: An assessment of sustained adherence among adolescents in  
582 South Africa. J Int AIDS Soc [Internet]. 2021 Oct 1 [cited 2023 Mar 4];24(10).  
583 Available from: [/pmc/articles/PMC8552454/](https://pmc/articles/PMC8552454/)

- 584 43. Cluver L, Meinck F, Toska E, Orkin FM, Hodes R, Sherr L. Multitype violence  
585 exposures and adolescent antiretroviral nonadherence in South Africa. *AIDS*.  
586 2018;32(8):975.
- 587 44. Gray KL, Kiazolu M, Jones J, Konstantinova A, Zawolo JSW, Gray WMH, et al.  
588 Liberia adherence and loss-to-follow-up in HIV and AIDS care and treatment:  
589 A retrospective cohort of adolescents and adults from 2016–2019. *PLOS*  
590 *Global Public Health*. 2022;2(3).
- 591 45. Kerschberger B, Schomaker M, Jobanputra K, Kabore SM, Teck R, Mabhena  
592 E, et al. HIV programmatic outcomes following implementation of the “Treat-  
593 All” policy in a public sector setting in Eswatini: a prospective cohort study. *J*  
594 *Int AIDS Soc* [Internet]. 2020 Mar 1 [cited 2023 Feb 8];23(3). Available from:  
595 <https://pubmed.ncbi.nlm.nih.gov/32128964/>
- 596 46. Horter S, Thabede Z, Dlamini V, Bernays S, Stringer B, Mazibuko S, et al. “Life  
597 is so easy on ART, once you accept it”: Acceptance, denial and linkage to HIV  
598 care in Shiselweni, Swaziland. *Soc Sci Med*. 2017 Mar 1; 176:52–9.
- 599 47. Barbara Sibbald. Responding to Swaziland’s dual epidemic. *CMAJ* [Internet].  
600 2013 Jan 1 [cited 2023 Feb 8];185(1): E13–4. Available from:  
601 <https://www.cmaj.ca/content/cmaj/185/1/E13.full.pdf>
- 602 48. PEPFAR. Eswatini Country Operational Plan (COP/ROP) 2020 Strategic  
603 Direction Summary. 2020.
- 604 49. Nabukeera-Barungi N, Elyanu P, Asire B, Katureebe C, Lukabwe I, Namusoke  
605 E, et al. Adherence to antiretroviral therapy and retention in care for

- 606 adolescents living with HIV from 10 districts in Uganda. *BMC Infect Dis.*  
607 2015;15(1):1–10.
- 608 50. Thirumurthy H, Ndyabakira A, Marson K, Emperador D, Kanya M, Havlir D, et  
609 al. Financial incentives for achieving and maintaining viral suppression among  
610 HIV-positive adults in Uganda: a randomised controlled trial. *Lancet HIV.* 2019  
611 Mar;6(3): e155–63.
- 612 51. Fahey CA, Njau PF, Katabaro E, Mfaume RS, Ulenga N, Mwenda N, et al.  
613 Financial incentives to promote retention in care and viral suppression in  
614 adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm  
615 randomised controlled trial. *Lancet HIV.* 2020 Nov;7(11): e762–71.
- 616 52. Bermudez LG, Jennings L, Ssewamala FM, Nabunya P, Mellins C, McKay M.  
617 Equity in adherence to antiretroviral therapy among economically vulnerable  
618 adolescents living with HIV in Uganda. *AIDS Care - Psychological and Socio-*  
619 *Medical Aspects of AIDS/HIV* [Internet]. 2016;28(sup2):83–91. Available from:  
620 <https://doi.org/10.1080/09540121.2016.1176681>
- 621 53. Linnemayr S, Stecher C, Mukasa B. Behavioral economic incentives to  
622 improve adherence to antiretroviral medication. *Aids.* 2017;31(5):719–26.
- 623 54. Bezabih T, Weiser SD, Menbere MS, Negash A, Grede N. Comparison of  
624 treatment adherence outcome among PLHIV enrolled in economic  
625 strengthening program with community control. *AIDS Care.* 2018  
626 Mar;30(3):369–77.
- 627 55. Cluver LD, Hodes RJ, Toska E, Kidia KK, Orkin FM, Sherr L, et al. “HIV is like  
628 a tsotsi. ARVs are your guns”: Associations between HIV-disclosure and

- 629 adherence to antiretroviral treatment among adolescents in South Africa. *Aids*.  
630 2015;29(April): S57–65.
- 631 56. Ramos J V, Mmbaga BT, Turner EL, Rugalabamu LL, Luhanga S,  
632 Cunningham CK, et al. Modality of Primary HIV Disclosure and Association  
633 with Mental Health, Stigma, and Antiretroviral Therapy Adherence in  
634 Tanzanian Youth Living with HIV. *AIDS Patient Care STDS*. 2018  
635 Jan;32(1):31–7.
- 636 57. Stangl AL, Mwale M, Sebany M, Mackworth-Young CRS, Chiiya C, Chonta M,  
637 et al. Feasibility, Acceptability and Preliminary Efficacy of Tikambisane (‘Let’s  
638 Talk to Each Other’): A Pilot Support Group Intervention for Adolescent Girls  
639 Living with HIV in Zambia. *J Int Assoc Provid AIDS Care*. 2021;20.
- 640 58. Merzel C, VanDevanter N, Irvine M. Adherence to antiretroviral therapy among  
641 older children and adolescents with HIV: A qualitative study of psychosocial  
642 contexts. *AIDS Patient Care STDS*. 2008;22(12).
- 643 59. Ankrah DNA, Koster ES, Mantel-Teeuwisse AK, Arhinful DK, Agyepong IA,  
644 Lartey M. Facilitators and barriers to antiretroviral therapy adherence among  
645 adolescents in Ghana. *Patient Prefer Adherence*. 2016; 10:329–37.
- 646 60. Xu L, Munir K, Kanabkaew C, Le Coeur S. Factors influencing antiretroviral  
647 treatment suboptimal adherence among perinatally HIV infected adolescents in  
648 Thailand. *PLoS One*. 2017;12(2):1–18.
- 649 61. Bvochora T, Satyanarayana S, Takarinda KC, Bara H, Chonzi P, Komtenza B,  
650 et al. Enhanced adherence counselling and viral load suppression in HIV  
651 seropositive patients with an initial high viral load in Harare, Zimbabwe:



- 652 Operational issues. PLoS One [Internet]. 2019 Feb 1 [cited 2023 Jan 24];14(2):  
653 e0211326. Available from:  
654 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211326>
- 655 62. Hussen S, Mama M, Mekonnen B, Yihune M, Shegaze M, Boti N, et al.  
656 Predictors of Time to Viral Load Suppression of Adult PLWHIV on ART in Arba  
657 Minch General Hospital: A Follow up Study. Ethiop J Health Sci [Internet].  
658 2019 Nov 19 [cited 2023 Jan 24];29(6):751–8. Available from:  
659 <https://www.ajol.info/index.php/ejhs/article/view/191325>
- 660 63. Diress G, Dagne S, Alemnew B, Adane S, Addisu A. Viral Load Suppression  
661 after Enhanced Adherence Counseling and Its Predictors among High Viral  
662 Load HIV Seropositive People in North Wollo Zone Public Hospitals, Northeast  
663 Ethiopia, 2019: Retrospective Cohort Study. AIDS Res Treat. 2020;2020.
- 664 64. Ross-Degnan D, Pierre-Jacques M, Zhang F, Tadege H, Gitau L, Ntaganira J,  
665 et al. Measuring adherence to antiretroviral treatment in resource-poor  
666 settings: The clinical validity of key indicators. BMC Health Serv Res. 2010;  
667 10:42.
- 668 65. Chalker JC, Andualem T, Gitau LN, Ntaganira J, Obua C, Tadege H, et al.  
669 Measuring adherence to antiretroviral treatment in resource-poor settings: The  
670 feasibility of collecting routine data for key indicators. BMC Health Serv Res  
671 [Internet]. 2010 Feb 19 [cited 2022 Oct 27];10(1):1–11. Available from:  
672 <https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-10-43>
- 673 66. Gebreyesus F, Mitku D, Tarekegn T, Temere B, Terefe T, Belete A, et al.  
674 Levels of Adherence and Associated Factors Among Children on ART Over

- 675 Time in Northwest, Ethiopia: Evidence from a Multicenter Follow-Up Study.  
676 2021 [cited 2022 Oct 25]; Available from: <https://doi.org/10.2147/HIV.S323090>
- 677 67. Ba J, Id V, Katsabola H, Bvumbwe Id M, Mhango J, Silverstein Id A, et al.  
678 Factors associated with antiretroviral therapy adherence among adolescents  
679 living with HIV in the era of isoniazid preventive therapy as part of HIV care.  
680 PLOS Global Public Health [Internet]. 2022 Jun 2 [cited 2022 Oct 18];2(6):  
681 e0000418. Available from:  
682 <https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.000>  
683 0418
- 684 68. Kabogo J, Muniu E, Wamunyokoli F, Musoke R, Songok E. Evidence of  
685 reduced treatment adherence among HIV infected paediatric and adolescent  
686 populations in Nairobi at the onset of the UNAIDS Universal Test and Treat  
687 Program. BMC Res Notes. 2018;11(1):1–7.
- 688 69. Alhaj M, Amberbir A, Singogo E, Banda V, van Lettow M, Matengeni A, et al.  
689 Retention on antiretroviral therapy during Universal Test and Treat  
690 implementation in Zomba district, Malawi: a retrospective cohort study. J Int  
691 AIDS Soc. 2019;22(2).
- 692 70. Havlir D, Lockman S, Ayles H, Larmarange J, Chamie G, Gaolathe T, et al.  
693 What do the Universal Test and Treat trials tell us about the path to HIV  
694 epidemic control? Vol. 23, Journal of the International AIDS Society. 2020.
- 695 71. Herce ME, Hoffmann CJ, Fielding K, Topp SM, Hausler H, Chimoyi L, et al.  
696 Universal test-and-treat in Zambian and South African correctional facilities: a  
697 multisite prospective cohort study. Lancet HIV. 2020;7(12).

- 698 72. Mugenyi L, Nanfuka M, Byawaka J, Agaba C, Mijumbi A, Kagimu D, et al.  
699 Effect of universal test and treat on retention and mortality among people living  
700 with HIV-infection in Uganda: An interrupted time series analysis. PLoS One  
701 [Internet]. 2022 May 1 [cited 2022 Oct 21];17(5): e0268226. Available from:  
702 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268226>
- 703 73. Barlow-Mosha L, Musiime V, Davies MA, Prendergast AJ, Musoke P, Siberry  
704 G, et al. Universal antiretroviral therapy for HIV-infected children: a review of  
705 the benefits and risks to consider during implementation. J Int AIDS Soc. 2017  
706 Jun;20(1):21552.
- 707